Further immune-based strategies rely on the anti-tumor activation of cytotoxic T-lymphocytes by antigen-presenting dendritic cells primed with tumor antigens or the adaptive T-cell therapy (ACT) with CAR-T cells targeting NY-ESO-1 or HER2 [348]. The gene discussed is ERBB2; the disease is neoplasm.